YKL -40 as New Biomarker in COVID -19 Patients

Assiut University

Status: Not yet enrolling

Conditions: COVID-19

Treatments: Device: Computerized Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT05137509

AHGNH

Details and patient eligibility

About

The coronavirus disease-2019 (COVID-19)is a pandemic disease caused by SARS -COV-2 which belongs to the β-coronavirus family . The majority of affected individuals exhibit no or mild to moderate symptoms, but up to 15% of patients develop severe pneumonia with approximately 6% progressing to acute respiratory distress syndrome and multiorgan failure.

Biomarkers are needed to identify patients will suffer rapid disease progression to severe complications and death. Preliminary studies describe vasculitic processes underlying organ damage in seriously ill patients, induced by the activation of inflammatory cascades, complement activation and pro-inflammatory cytokines (i.e. interleukin).

The severity of Vasculitic damage is unfortunately not easily predictable through currently used laboratory biomarkers such as D-dimer or prothrombin time/activated partial thromboplastin time.

The severity of the disease is mainly driven by diffuse interstitial lung diseases. YKL-40 has a pro mitogenic action on pulmonary fibroblasts, increases the activity of macrophages and is associated with inflammatory disorders. In ILD, YKL-40 has been described to be associated with the severity of lung diseases and with the risk of death.

YKL-40 serum levels could therefore be of interest for diagnosis and prognosis since it is at the cross-link between vascular and epithelial lung damage.

.

Enrollment: 100 estimated patients

Sex: All

Ages: Under 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Group one should be diagnosed by RT-PCR (reverse transcriptase polymerase chain reaction).

  • Healthy individual must be without a prior history of chronic inflammation in the lung.

Exclusion criteria

• Patients with acute renal failure (ARF) or multiple organ damage (MOF).

Trial design

100 participants in 3 patient groups

Patients Infected by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)

Description:

Patients Infected by COVID -19 diagnosed by Reverse transcriptase polymerase chain reaction and computerized tomography

Treatment:

Device: Computerized Tomography

patients suffering from chronic lung disease

Description:

Diagnosed by clinical manifestation and Computerized tomogarphy

Treatment:

Device: Computerized Tomography

Healthy Individuals

Description:

They must be without prior history of chronic inflammation in the lung